Table 3.
Estimated effects of each variable on longitudinal remission.
| Direction of Effect in Non-Discretized Longitudinal Remission Model | Exact Effect Size in Discretized Longitudinal Remission Model (Lowest vs. Highest) | Effect for Group with Lowest Value | Effect for Group with Highest Value | |
|---|---|---|---|---|
| HBI at the first UST dose, categorised | Negative | Negative: −2.32 | 1.09 (0.91, 1.27) | 0.14 (−0.04, 0.32) |
| Years between diagnosis and start of UST | Negative | Not significant, trending negative | 0.06 (−0.05, 0.17) | −0.06 (−0.17, 0.05) |
| Number of surgeries before UST treatment onset | Negative | −0.33 | 0.19 (0.06, 0.33) | −0.14 (−0.33, 0.05) |
| Number of anti-TNF episodes | Negative | Borderline insignificant, trending negative | 0.11 (−0.01, 0.24) | −0.11 (−0.24, 0.01) |
| Number of anti-integrin episodes | Negative | Negative: −1.96 | 0.7 (0.19, 1.22) | −1.26 (−2.27, −0.25) |
| Age at the time of signing consent | Negative | Negative: −0.31 | 0.16 (0.06, 0.26) | −0.16 (−0.26, −0.06) |
| BMI at baseline | Negative | Negative: −2 | 0.8 (0.52, 1.09) | −1.2 (−1.73, −0.68) |
| Sex | Insignificant | N/A | N/A | N/A |
| Number of comorbidities | Negative | Negative: −0.41 | 0.22 (0.06, 0.38) | −0.19 (−0.44, 0.07) |
| Perianal disease | Negative | Negative: −0.7 | 0.35 (0.21, 0.48) | −0.35 (−0.48, −0.21) |
| Location of CD (no ileal involvement) | Positive | Positive: 0.74 | −0.37 (−0.52, −0.23) | 0.37 (0.23, 0.52) |
| Patient ever had EIMs | Insignificant | N/A | N/A | N/A |
| Family history of CD | Insignificant | N/A | N/A | N/A |
| Upper gastrointenstinal tract (L4) involved | Insignificant | N/A | N/A | N/A |
| Baseline albumin | Negative | Negative: −0.13 | 0.07 (−0.03, 0.16) | −0.07 (−0.16, 0.03) |
| Baseline faecal calprotectin | Negative | Negative: −0.45 | 0.28 (0.02, 0.53) | −0.17 (−0.33, −0.0) |
| Baseline hemoglobin | Positive | Positive: 0.08 | −0.04 (−0.19, 0.11) | 0.04 (−0.11, 0.19) |
| Baseline CRP | Positive | Positive: 0.6 | −0.32 (−0.53, −0.11) | 0.28 (0.14, 0.43) |
| Under Steroids at first UST dose | Positive | Positive: 0.69 | −0.35 (−0.48, −0.22) | 0.35 (0.22, 0.48) |
| Under Immunosuppressants at first UST dose | Negative | Negative: −0.28 | 0.14 (0.04, 0.23) | −0.14 (−0.23, −0.04) |
| Number of concomitant Steroid courses | Negative | Negative: −0.83 | 0.42 (0.29, 0.54) | −0.42 (−0.54, −0.29) |
For factors with more than 2 values, the difference in log-odds of remission between patients in the group with the highest value vs. those with the lowest value are reported. BMI, Body Mass Index; CD, Crohn’s Disease; CRP, C-reactive protein; EIM, extraintestinal manifestation; HBI, Harvey Bradshaw Index; TNF, Tumor Necrosis Factor; UST, ustekinumab.